Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study

Authors

Abdel G. Babiker, MRC Clinical Trials Unit, London, UK
Sean Emery, University of New South Wales, Sydney, Australia
Gerd Fätkenheuer, University of Cologne, Cologne, Germany
Fred M. Gordin, George Washington University
Birgit Grund, University of Minnesota
Jens D. Lundgren, University of Copenhagen, Denmark
James D. Neaton, University of Minnesota
Sarah L. Pett, University of New South Wales, Sydney, Australia
Andrew Phillips, UCL Medical School, London, UK
Giota Touloumi, Athens University Medical School, Athens, Greece
Michael J. Vjecha, Veterans Affairs Medical Center

Document Type

Journal Article

Publication Date

4-30-2012

Journal

Clinical Trials

Keywords

Anti-Retroviral Agents--therapeutic use; HIV Infections--drug therapy; Multicenter Studies as Topic--methods; Randomized Controlled Trials as Topic--methods; Research Design

Comments

This is an open access PubMed Central article. Click on link for full-text access.

APA Citation

Babiker, A., Emery, S., Fätkenheuer, G., Gordin, F., Grund, B., Lundgren, J., Neaton, J., & Pett, S. (2012). Considerations in the rationale, design and methods of the strategic timing of antiretroviral treatment (start) study. Clinical Trials,

Peer Reviewed

1

Open Access

1